new 12 month closing high, page-13

the company i use to benchmark stocks in the bio area is cellestis cst if you look at its mkt cap based on about $10m net profit and its history of growth and forward potential,then clearly ado has some way to run .all we need now is something a little more concrete in terms of forward earnings.ado potential far exceeds that of cst so once we get some guidance we should see a strong rerate.by way of aside i see 2011 as the year when finally a number of aussie biotechs make the grade along with ado i hold
large postions in qrx,pyc and obj all seem to me to have enormous potential.